COA_Karl said:The GIP arm is doing real work rather than padding the label.
Careful with treating an unchanged LDL-C as a failure. If ApoB and triglycerides both fell, the particle picture improved regardless of what the calculated LDL says.
Adding the numbers, since they settle part of this. Practical numbers: half-life about 5 days, steady state 3 to 4 weeks, ladder 2.5 / 5 / 7.5 / 10 / 12.5 / 15mg, and the maintenance doses with published data behind them are 5, 10 and 15mg.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Dr.ReproEndo said:Careful with treating an unchanged LDL-C as a failure.
There is a second half to this that has not been said yet. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsA narrower follow-up, since the general answer is now clear:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?
Closing the loop on my own question.
Reporting back after another eight months at the same dose. Still losing slowly, no new side effects, and no reason I can find to climb further.